Jiuzhou Pharmaceutical Welcomes RayHua to Become a Group Member
Chinese CDMO Jiuzhou Pharmaceutical said it plans to buy a Sandoz finished drugs plant in Zhongshan in southern China for $15.1 million, according to a securities filing (PDF, Chinese) to the Shanghai Stock Exchange.
Another Novartis ingredient operation is being hived off as the Swiss drugmaker continues its drive to lop off manufacturing jobs to improve margins. This time it is selling an operation in China that it opened 10 years ago.
Bal Pharma Limited (Bal Pharma), the largest Indian pharmaceutical producer of the bulk drug Gliclazide, an oral hypoglycemic (anti-diabetic drug) claimed victory for the recent imposition of Anti-Dumping Duty imposed by the Indian Ministry of Finance on imports of the bulk substance from China. According to a filing with the Bombay Stock Exchange, Bal Pharma, with manufacturing facilities located in Bangalore, Pune and Uttaranchal, manufactures Gliclazide at its Bangalore facility for both domestic and certain overseas markets.